|
1
|
Steinman RM and Banchereau J: Taking
dendritic cells into medicine. Nature. 449:419–426. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banchereau J and Palucka AK: Dendritic
cells as therapeutic vaccines against cancer. Nat Rev Immunol.
5:296–306. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iwahashi M, Katsuda M, Nakamori M, et al:
Vaccination with peptides derived from cancer-testis antigens in
combination with CpG-7909 elicits strong specific CD8+ T
cell response in patients with metastatic esophageal squamous cell
carcinoma. Cancer Sci. 101:2510–2517. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kono K, Mizukami Y, Daigo Y, et al:
Vaccination with multiple peptides derived from novel cancer-testis
antigens can induce specific T-cell responses and clinical
responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Turtle CJ and Riddell SR: Genetically
retargeting CD8+ lymphocyte subsets for cancer
immunotherapy. Curr Opin Immunol. 23:299–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Villarroel-Dorrego M, Speight PM and
Barrett AW: Expression of major histocompatibility complex class II
and costimulatory molecules in oral carcinomas in vitro. Med Oral
Patol Oral Cir Bucal. 10:188–195. 2005.PubMed/NCBI
|
|
7
|
Mimura K, Ando T, Poschke I, et al: T cell
recognition of HLA-A2 restricted tumor antigens is impaired by the
oncogene HER2. Int J Cancer. 128:390–401. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Slavin-Chiorini DC, Catalfamo M,
Kudo-Saito C, Hodge JW, Schlom J and Sabzevari H: Amplification of
the lytic potential of effector/memory CD8+ cells by
vector-based enhancement of ICAM-1 (CD54) in target cells:
implications for intratumoral vaccine therapy. Cancer Gene Ther.
11:665–680. 2004.PubMed/NCBI
|
|
9
|
Malvicini M, Alaniz L, Bayo J, et al:
Single low-dose cyclophosphamide combined with interleukin-12 gene
therapy is superior to a metronomic schedule in inducing immunity
against colorectal carcinoma in mice. Oncoimmunology. 1:1038–1047.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O’Neill DW, Adams S and Bhardwaj N:
Manipulating dendritic cell biology for the active immunotherapy of
cancer. Blood. 104:2235–2246. 2004.PubMed/NCBI
|
|
11
|
Xu Q, Liu G, Yuan X, et al:
Antigen-specific T-cell response from dendritic cell vaccination
using cancer stem-like cell-associated antigens. Stem Cells.
27:1734–1740. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Williams BJ, Bhatia S, Adams LK, et al:
Dendritic cell based PSMA immunotherapy for prostate cancer using a
CD40-targeted adenovirus vector. PLoS One. 7:e469812012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noguchi T, Kato T, Wang L, et al:
Intracellular tumor-associated antigens represent effective targets
for passive immunotherapy. Cancer Res. 72:1672–1682. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee WT: Dendritic cell-tumor cell fusion
vaccines. Adv Exp Med Biol. 713:177–186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mou Y, Chen B, Zhang Y, et al: Influence
of synthetic superparamagnetic iron oxide on dendritic cells. Int J
Nanomedicine. 6:1779–1786. 2011.PubMed/NCBI
|
|
16
|
Benencia F, Courrèges MC and Coukos G:
Whole tumor antigen vaccination using dendritic cells: comparison
of RNA electroporation and pulsing with UV-irradiated tumor cells.
J Transl Med. 6:212008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mou Y, Hou Y, Chen B, et al: In vivo
migration of dendritic cells labeled with synthetic
superparamagnetic iron oxide. Int J Nanomedicine. 6:2633–2640.
2011.PubMed/NCBI
|
|
18
|
Verdijk P, Aarntzen EH, Lesterhuis WJ, et
al: Limited amounts of dendritic cells migrate into the T-cell area
of lymph nodes but have high immune activating potential in
melanoma patients. Clin Cancer Res. 15:2531–2540. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Creusot RJ, Yaghoubi SS, Chang P, et al:
Lymphoid-tissue-specific homing of bone-marrow-derived dendritic
cells. Blood. 113:6638–6647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huck SP, Tang SC, Andrew KA, Yang J,
Harper JL and Ronchese F: Activation and route of administration
both determine the ability of bone marrow-derived dendritic cells
to accumulate in secondary lymphoid organs and prime
CD8+ T cells against tumors. Cancer Immunol Immunother.
57:63–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimizu K, Kuriyama H, Kjaergaard J, Lee
W, Tanaka H and Shu S: Comparative analysis of antigen loading
strategies of dendritic cells for tumor immunotherapy. J
Immunother. 27:265–272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Z, Liu S, Mai X, Hu Z and Liu C:
Anti-tumor effects of fusion vaccine prepared by renal cell
carcinoma 786-O cell line and peripheral blood dendritic cells of
healthy volunteers in vitro and in human immune reconstituted SCID
mice. Cell Immunol. 262:112–119. 2010. View Article : Google Scholar
|
|
23
|
Deng YJ, Zhang LJ, Su XD, et al: Dendritic
cell-tumor cell fusion vaccine prevents growth of subcutaneous
transplanted esophageal carcinomas. Ai Zheng. 28:1067–1071.
2009.(In Chinese).
|
|
24
|
Koido S, Tanaka Y, Chen D, Kufe D and Gong
J: The kinetics of in vivo priming of CD4 and CD8 T cells by
dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol.
168:2111–2117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koido S, Hara E, Torii A, et al: Induction
of antigen-specific CD4- and CD8-mediated T-cell responses by
fusions of autologous dendritic cells and metastatic colorectal
cancer cells. Int J Cancer. 117:587–595. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koido S, Ohana M, Liu C, et al: Dendritic
cells fused with human cancer cells: morphology, antigen
expression, and T cell stimulation. Clin Immunol. 113:261–269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phan V, Errington F, Cheong SC, et al: A
new genetic method to generate and isolate small, short-lived but
highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med.
9:1215–1219. 2003. View
Article : Google Scholar : PubMed/NCBI
|
